A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination With Pembrolizumab in Subjects With Advanced, Relapsed, or Refractory Solid Tumors
Latest Information Update: 11 Jun 2024
At a glance
- Drugs IO-202 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Immune-Onc Therapeutics
- 31 May 2024 Status changed from active, no longer recruiting to completed.
- 11 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.